Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of ALXN2050 180 mg vs 60 mg and Food Effect in Healthy Adults
NCT05578846Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) and myasthenia gravis (MG) (6 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration at Day 4, Area under the concentration time curve to last quantifiable concentration at Day 4 and 6 more. Started Oct 2022; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05578846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578846.